NIH experts describe influenza vaccines of the future

Nov 17, 2010

In a review article appearing in the New England Journal of Medicine, scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, examine research under way to address the limitations of currently available influenza vaccines and develop more efficient and reliable strategies to make vaccines to protect against seasonal as well as pandemic influenza.

Although licensed seasonal flu vaccines safely and effectively protect most people who receive them from illness and death, the degree of protection varies depending on how well the circulating virus strains and those in the vaccine match. A vaccine recipient's age and health status also can affect the effectiveness of .

The authors discuss the spectrum of ongoing research that may transform the field in decades to come. Efforts to grow the vaccine virus in cells rather than eggs are currently under way and there is consideration of the addition to influenza vaccine of immune-stimulating adjuvants to be used in certain groups of individuals. Other approaches under development include influenza vaccines based on recombinant virus proteins, non-infectious virus-like particles, harmless vectors or influenza DNA. Also under intense study is the ultimate goal, a so-called universal that would provide protection against multiple strains of influenza, reducing the need for yearly flu shots while simultaneously protecting against novel flu viruses that may arise in the future.

To further protect vulnerable populations such as the elderly and those with underlying chronic diseases from seasonal influenza, as well as to quickly control the spread of potential viruses, influenza vaccine makers of the future must employ novel production technologies, the authors note.

Explore further: FDA OKs Cubist antibiotic for serious infections

More information: AS Fauci and L Lambert. Influenza vaccines for the future. New England Journal of Medicine DOI: 10.1056/ NEJMra1002842 (2010).

Provided by National Institutes of Health

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Universal flu vaccine holds promise

Apr 27, 2009

An influenza vaccine that protects against death and serious complications from different strains of flu is a little closer to reality, Saint Louis University vaccine researchers have found.

Recommended for you

FDA OKs Cubist antibiotic for serious infections

22 hours ago

The Food and Drug Administration has approved a new medicine to fight complex infections in the abdomen and urinary tract, the fourth antibiotic the agency has approved since May.

Xtoro approved for swimmer's ear

Dec 18, 2014

(HealthDay)—Xtoro (finafloxacin otic suspension) eardrops have been approved by the U.S. Food and Drug Administration to treat swimmer's ear, clinically known as acute otitis externa.

Drug interaction identified for ondansetron, tramadol

Dec 18, 2014

(HealthDay)—In the early postoperative period, ondansetron is associated with increased requirements for tramadol consumption, according to a review and meta-analysis published online Dec. 10 in Anaesthesia.

New system targets germs in donated blood plasma

Dec 17, 2014

(HealthDay)—A new system designed to eliminate germs in donated blood plasma and reduce the risk of transmitting a plasma-borne infection has been approved by the U.S. Food and Drug Administration.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.